A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Exclusion Criteria

• •1. Uveal melanoma
• •2. Any evidence of residual disease after surgery by imaging, pathology, or cytology.
• •3. Ongoing or recent (within 2 years) evidence of clinically significant autoimmune disease that required treatment
• •4. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection, as described in the protocol
• •5. Another malignancy that is currently progressing or that required active treatment in the past 5 years, as described in the protocol
• •6. Participants with a history of myocarditis
• •7. Adolescent patients (≥12 to \<18 years old) with body weight \<40 kg